Brought to you by 
Lupin gets exclusive rights to sell Romark's Alinia in the US
08 Aug 2013
Executive Summary
Romark Laboratories LC (developing therapies for infectious diseases and cancer) has licensed Indian pharmaco Lupin Ltd. exclusive rights to promote and distribute Alinia (nitazoxanide) oral suspension 100 mg/5ml in the US.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lupin gets exclusive rights to sell Romark's Alinia in the US
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice